Page 469 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Berge 231 SEER- WW vs. RP 1991-92 12,711 cT1-2 or pT1-3, age ≥65, Median age: WW, 77; RP, 70; C
2007 Medicare vs. RT vs. continuously enrolled on RT, 74
a
17178188 ADT 5 yr Medicare for the entire study
period. Excluded patients PSA: NR
Retrospective enrolled in an HMO, those with
cohort primary treatment discrepancy Grade: WW, well dif., 40.2%;
between SEER and Medicare moderately dif., 40.8%; poorly
data, those who died before the dif., 10.3%; undiff, 0.6%;
end of the study period, patients unknown, 8.2%. RP, well dif.,
with metastatic disease, and 10.2%; moderately dif., 67.6%;
those with tumors clinically poorly dif., 20.5%; undiff, 0.5%;
classified as extension through unknown, 1.2%. RT, well dif.,
capsule or with positive lymph 20.5%; moderately dif., 58.1%;
nodes (only for the non-RP poorly dif., 15.7%; undiff, 0.6%;
groups). unknown, 5.0%.

Patients with pT3 tumors were Stage: WW, In situ, 0.9%; T1/2,
included only in the surgical arm 99.1; pT3, 0%. RP, In situ, 0.1;
to account for the lack of T1/2, 54.6; pT3, 45.4%. RT, In
pathologic staging in patients situ, 0%; T1/2, 100%; pT3, 0%.
receiving other treatments.
Elliott 218 CaPSURE (RP, Median 6597 Newly diagnosed with prostate Age: <60 yr, 25%; 60-59, 40%; B
2007 RP+EBRT, 2.7 yr cancer between 1995 and 2006 ≥70 yr, 35%
17570425 cryotherapy, (range 3 with complete diagnostic and
BT, days to treatment clinical data available, PSA: ≤4, 14%; 4.1-10.0, 62%;
Retrospective BT+EBRT, 10.9 yr) and without a history of urethral 10.1-20.0, 16%; >20, 8%
cohort EBRT, or stricture
hormones) Gleason score: 2-6, 65%; 7,
vs. WW 26%; 8-10, 9%

Stage: T1, 53%; T2, 45%; T3a,
2%

a We did not extract data from the group of patients receiving primary ADT as the only initial therapy.

C-152